Clinical Trial Update: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating a combination of anti-PD-1 therapy and aldesleukin (IL-2) for metastatic melanoma and metastatic renal cell carcinoma; recruitment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Anti-PD-1 therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Advanced Locoregional Melanoma | Phase 2 | Status: RECRUITING